Corporate News 2
Corporate News 2
Aurobindo Pharma receives USFDA nod for conjunctivitis drug : Aurobindo Pharma, a mid-size pharmaceutical company, announced that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market a drug indicated in the treatment of seasonal allergic conjunctivitis. The company said, "Received final approval from the USFDA to manufacture and market Olopatadine Hydrochloride Ophthalmic solution USP, 0.1%. This product is ready for launch." The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Patanol Ophthalmic solution, 0.1%, of Alcon Laboratories, Inc. According to IMS, the approved product has an estimated market size of USD 235 million for the twelve months ending October 2015.
Glenmark Pharma receives USFDA approval for Linezolid tablets : Glenmark Pharmaceuticals (Glenmark), a manufacturer of generic formulation products and API, has been granted final approval by the United States Food & Drug Administration (USFDA) for Linezolid tablets, 600 mg. Linezolid tablets are the therapeutic equivalent of Zyvox Tablets, 600 mg of Pharmacia and Upjohn Company, a subsidiary of Pfizer Inc. According to IMS Health sales data for the 12 month period ending October 2015, the Zyvox tablets, 600 mg market1 achieved annual sales of approximately USD 447.6 million. Glenmark's current portfolio consists of 104 products authorized for distribution in the U.S. marketplace and 62 ANDA's pending approval with the USFDA.
Rcom plans to merge Indian wireless biz with Aircel : Anil Ambani led Reliance Communications (RCom), one of the leading telecom operators in India is in plans to merge their Indian wireless business with Aircel to mutually derive the expected substantial benefits of in country consolidation, including opex and capex synergies and revenue enhancement. In this regards, the company said, "Entered into a 90-day exclusivity period with Maxis Communications Berhad (MCB) and Sindya Securities and Investments, the shareholders of Aircel to consider the potential combination of the Indian wireless business of RCom and Aircel." The potential combination will exclude RCom's towers and optical fibre infrastructure, for which RCOM is proceeding with an asset sale, as announced on Dec. 4, 2015. "The discussions are non-binding in nature. Any transaction will be subject to due diligence, definitive documentation and regulatory, shareholders' and other third party approvals. Hence, there is no certainty that any transaction will result," the company added.
Cipla launches generic hepatitis C drug 'Hepcvir-L' : Cipla, a leading drug maker, on Monday announced the launch of generic drug Ledipasvir-Sofosbuvir indicated for the treatment of hepatitis C in India under the brand name Hepcvir-L. HepcvirL is the first once-a-day, fixed-dose oral combination therapy that has been approved for chronic hepatitis C genotype 1 patients. Subhanu Saxena, MD & Global CEO, Cipla said, "Cipla has always tried to provide best-in-class affordable medicines to patients and the launch of Ledipasvir-Sofosbuvir is a further step to facilitate the optimal treatment for patients suffering from genotype 1 hepatitis C virus." The introduction of the Ledipasvir-Sofosbuvir fixed-dose oral combination thereby provides a new interferon and ribavirin-free treatment option to patients and is a powerful weapon to fight against genotype 1 hepatitis C virus.
HDIL surges 5% on sale of land parcel to DK Realty : Housing Development and Infrastructure (HDIL), the real estate development company in India, witnessed a rise in share price on Tuesday after the company has sold a land property situated in Kurla, Mumbai to DK Realty for a consideration of Rs 6.50 billion. The company said, ''Registered a development agreement with DK Realty to sell the development rights in respect of the piece and parcel of land situated at Kurla.''
Aurobindo Pharma receives USFDA nod for conjunctivitis drug : Aurobindo Pharma, a mid-size pharmaceutical company, announced that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market a drug indicated in the treatment of seasonal allergic conjunctivitis. The company said, "Received final approval from the USFDA to manufacture and market Olopatadine Hydrochloride Ophthalmic solution USP, 0.1%. This product is ready for launch." The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Patanol Ophthalmic solution, 0.1%, of Alcon Laboratories, Inc. According to IMS, the approved product has an estimated market size of USD 235 million for the twelve months ending October 2015.
Glenmark Pharma receives USFDA approval for Linezolid tablets : Glenmark Pharmaceuticals (Glenmark), a manufacturer of generic formulation products and API, has been granted final approval by the United States Food & Drug Administration (USFDA) for Linezolid tablets, 600 mg. Linezolid tablets are the therapeutic equivalent of Zyvox Tablets, 600 mg of Pharmacia and Upjohn Company, a subsidiary of Pfizer Inc. According to IMS Health sales data for the 12 month period ending October 2015, the Zyvox tablets, 600 mg market1 achieved annual sales of approximately USD 447.6 million. Glenmark's current portfolio consists of 104 products authorized for distribution in the U.S. marketplace and 62 ANDA's pending approval with the USFDA.
Rcom plans to merge Indian wireless biz with Aircel : Anil Ambani led Reliance Communications (RCom), one of the leading telecom operators in India is in plans to merge their Indian wireless business with Aircel to mutually derive the expected substantial benefits of in country consolidation, including opex and capex synergies and revenue enhancement. In this regards, the company said, "Entered into a 90-day exclusivity period with Maxis Communications Berhad (MCB) and Sindya Securities and Investments, the shareholders of Aircel to consider the potential combination of the Indian wireless business of RCom and Aircel." The potential combination will exclude RCom's towers and optical fibre infrastructure, for which RCOM is proceeding with an asset sale, as announced on Dec. 4, 2015. "The discussions are non-binding in nature. Any transaction will be subject to due diligence, definitive documentation and regulatory, shareholders' and other third party approvals. Hence, there is no certainty that any transaction will result," the company added.
Cipla launches generic hepatitis C drug 'Hepcvir-L' : Cipla, a leading drug maker, on Monday announced the launch of generic drug Ledipasvir-Sofosbuvir indicated for the treatment of hepatitis C in India under the brand name Hepcvir-L. HepcvirL is the first once-a-day, fixed-dose oral combination therapy that has been approved for chronic hepatitis C genotype 1 patients. Subhanu Saxena, MD & Global CEO, Cipla said, "Cipla has always tried to provide best-in-class affordable medicines to patients and the launch of Ledipasvir-Sofosbuvir is a further step to facilitate the optimal treatment for patients suffering from genotype 1 hepatitis C virus." The introduction of the Ledipasvir-Sofosbuvir fixed-dose oral combination thereby provides a new interferon and ribavirin-free treatment option to patients and is a powerful weapon to fight against genotype 1 hepatitis C virus.
HDIL surges 5% on sale of land parcel to DK Realty : Housing Development and Infrastructure (HDIL), the real estate development company in India, witnessed a rise in share price on Tuesday after the company has sold a land property situated in Kurla, Mumbai to DK Realty for a consideration of Rs 6.50 billion. The company said, ''Registered a development agreement with DK Realty to sell the development rights in respect of the piece and parcel of land situated at Kurla.''
.jpeg)
.jpeg)
Comments
Post a Comment